Vanda Pharmaceuticals Gets FDA Approval for Bipolar, Schizophrenia Treatment

Vanda Pharmaceuticals received Food and Drug Administration approval on Friday for Bysanti tablets, a new treatment option for both bipolar I disorder and schizophrenia in adults.

New Treatment for Serious Mental Health Conditions

The approval covers the acute treatment of manic or mixed episodes associated with bipolar I disorder, a condition affecting a significant portion of the roughly 10 million Americans living with bipolar disorder. Bysanti is also approved for the treatment of schizophrenia, which impacts approximately 1% of the adult population – around 2.8 million people – and can lead to significant challenges in daily life, including frequent hospitalizations and reduced quality of life.

Did You Know? The latest patent protecting Bysanti is expected to remain in effect until 2044.

Vanda anticipates that Bysanti will be available for prescription in the third quarter of this year. The company believes its marketing exclusivity will be protected through regulatory data exclusivity and a series of U.S. Patents.

Further Research Underway

Beyond bipolar I disorder and schizophrenia, Vanda Pharmaceuticals is also investigating Bysanti as a potential treatment for treatment-resistant major depressive disorder. An ongoing clinical study evaluating Bysanti as an adjunctive, once-daily treatment is expected to conclude by the end of 2026.

Expert Insight: The FDA approval of Bysanti represents a potential step forward in addressing the complex needs of individuals living with bipolar I disorder and schizophrenia, conditions that often require ongoing and multifaceted treatment approaches.

Frequently Asked Questions

What conditions does Bysanti treat?

Bysanti is approved for the acute treatment of manic or mixed episodes associated with bipolar I disorder and for the treatment of schizophrenia in adults.

When will Bysanti be available?

Vanda Pharmaceuticals expects Bysanti to be commercially available in the third quarter of this year.

Is Vanda researching other uses for Bysanti?

Yes, Vanda is currently conducting a clinical study to evaluate Bysanti as a treatment for treatment-resistant major depressive disorder, with results expected by the end of 2026.

How might new treatment options impact the lives of those affected by these mental health conditions?